← All trials
NCT05284799
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 9, 2022
- Primary completion
- Jul 19, 2022
- Completion date
- Dec 9, 2022
- First posted
- Mar 17, 2022
- Last posted
- Dec 16, 2022
- Enrollment
- 180
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Osivax S.A.SLead sponsor
- Harmony Clinical ResearchCollaborator
- NovotechCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.